


**WE WANT TO CURE**  
**CANCER**  
*WITH OUR*  
**LOW SIDE EFFECT**  
**NANOMEDICINES**




Sena Nomak  
Co-Founder, COO  
[sn@rsresearch.net](mailto:sn@rsresearch.net)



Rana Sanyal  
Co-Founder, CSO  
[rs@rsresearch.net](mailto:rs@rsresearch.net)

# RS Research Drug Delivery Platform - I



# Business Model

## Low Risk Business Model:

Prodrugs from clinically proven chemo agents

## Superior Results:

Improved side effect profile

Increased efficacy

## Novel Product:

Proprietary nanocarrier-linker-drug combination

Targeted chemotherapy

Protected with platform patents and FTO

GB, PCT



# Pipeline


Drug Candidate	Research	Preclinical	IND Approval	Clinical	Platform	Proposed Indication
RS-0139	██████████	██████████	██████████		I	NSCL CA Breast CA Prostate CA
RS-0337	██████████	██████████			II	Breast CA
RS-0461	██████████	██████████			II	Ovarian CA
RS-0625	██████████	██████████			I	Ovarian CA
RS-0583	██████████	██████████			I	Pancreas CA



# Leading Candidate RS-0139 Shows Favorable Toxicity & Superior Efficacy

## Very encouraging short term tox



Percent Hemogram Change (after 24 h)



RS-0139 Released Drug

Cytotoxic Drug

Advantageous biodistribution : Considerably less released drug compared to when the drug is administered alone as currently used in clinic = **Less toxicity in healthy organs!**



No tumor observed in any of the RS-0139 mice @ Day 255!

# Timeline

